基因1型慢性丙型肝炎血清MicroRNA-122的表达与干扰素应答的相关性研究  

PBMCs microRNA-122 level correlates with virological responses to pegylated interferon alpha therapy in patients with hepatitis C genotype 1b

作　　者：李剑萍[1] 潘能浪 谢志伟[1] 杨可立[1] 关玉娟[1] 唐小平[1] 

机构地区：[1]广州市第八人民医院肝病科,510060

出　　处：《中华实验和临床病毒学杂志》2017年第6期549-553,共5页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的 探讨血清miR-122水平与聚乙二醇干扰素抗病毒治疗应答的相关性及分析聚乙二醇干扰素联合利巴韦林病毒应答的预测因素.方法 40例1b型慢性丙型肝炎患者纳入研究,所有患者均接受聚乙二醇干扰素α（聚乙二醇干扰素α-2 a或聚乙二醇干扰素α-2b）联合利巴韦林抗病毒治疗48周,随访24周;根据治疗结束后随访24周血清HCVRNA结果,分为持续病毒学应答（SVR）组和非持续病毒学应答（NSVR）组,比较SVR组和NSVR组miR-122水平及其他指标水平.结果 29例患者获得SVR,11例患者为NSVR;SVR组与NSVR组比较,基线HCV RNA载量、总胆红素水平（TBIL）、甲胎蛋白（AFP）水平、肝脏硬度值、层粘连蛋白水平均更低,差异有统计学意义（P＜0.05）,基线血清miR-122水平亦更低,但差异无统计学意义（P＞0.05）.并且在基线血清miR-122水平与基线HCV RNA载量、体重指数（BMI）、丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、肝脏纤维化程度无显著相关性（P＞0.05）.结论 基线HCV RNA载量、肝脏硬度值、总胆红素水平、甲胎蛋白水平可预测聚乙二醇干扰素联合利巴韦林的疗效,血清miR-122无明显的预测效果,且不能反映慢性丙型肝炎患者炎症反应活跃情况.Objective To clarify the predictive power of PBMCs miR-122,as well as other clinical factors,for response to IFNα therapy in chronic HCV infected patients.Methods A total of 40 patients chronically infected with HCV genotype 1b were enrolled.All the patients received pegylated interferon alpha （PEG-IFN α） in combination with ribavirin for 48 weeks.To perform the analyses,the patients were compared in terms of achieving sustained virological response （SVR） or not （NSVR） at 24th week after antiviral treatment.Results SVR rate was 72.5％ （29/40） and NSVR rate was 27.5％ （11/40）.SVR group experienced significantly lower HCV viral load,total bilirubin （TBIL）,alpha fetal protein （AFP）,fibroscan and laminin （LN） compared with NSVR group before treatment （P ＜ 0.05）.PBMCs miR-122 expression level was also lower in SVR group than that in SNVR group,although the difference was not statistically significant （P ＞ 0.05）.and there was no significant change of miR-122 level from baseline to the last available measurement between SVR group and NSVR group.However,no significant association was found between baseline PBMCs miR-122 and HCV viral load,body mass index （BMI）,alanine transaminase （ALT）,aspartate transaminase （AST）,degree of liver fibrosis,respectively.Conclusions Our result suggest that PBMCs miR-122 level is not an efficient biomarker to predict response to IFN alpha therapy in chronic HCV patients.However,baseline HCV viral load,TBIL,AFP and fibroscan may serve as predictive factors.

关 键 词：MIR-122 丙型肝炎 聚乙二醇干扰素Α 利巴韦林 

分 类 号：R512.63[医药卫生—内科学]